Connect With a Global Community of 400+ mRNA Experts

Demand for bespoke services and solutions is increasing exponentially as the mRNA industry continues to progress, targeting indications beyond infectious disease, and expanding applications through innovative approaches such as gene editing, cell engineering and protein replacement therapy.

Meet Senior Decision Makers

C-level executives and senior decision makers are actively seeking partners to support their pipelines and advance their mRNA candidates through to commercialization. As the largest gathering of mRNA experts globally, the 4th mRNA-Based Therapeutics Summit provided the ultimate platform for you to engage with leading biopharma and stakeholders across the drug development pipeline. Seize the opportunity in 2025 to showcase your innovative solutions to a global audience spanning C-level through to scientists.

mRNA23-958

Key Interest Areas

Our drug developer attendees are looking for service and solution providers with capabilities in the below areas.

Trailblazing mRNA-LNP Design, Screening & Snthesis Methods

Optimizing Analytical Tools for mRNA Release & Nanoparticle Stability

Harmonizing Regulatory Documentation Guidance to De-Risk mRNA Drug Approval

Pioneering Delivery Solutions & Platform Innovations

Improving Pre-Clinical Assays for Potency & Immunogenicity Studies

Advancing Clinical Trial Development & Recruitment

Improving Pre-Clinical Assays for Potency & Immunogenicity Studies

Advancing Clinical Trial Development & Recruitment

Confirmed Attendee Companies

thermo-fisher-scientific
Cy
Kindeva
resilience
sartorius-logo
prog
henvo

Beam Therapeutics
BeiGene
BioNTech AG
Daiichi Sankyo, Inc.
Pfizer
Moderna
Roche

thermo-fisher-scientific
Cy
Kindeva
resilience

BeiGene
Pfizer
Moderna
BioNTech AG

Audience Composition

Company Type

mrna-Company-Breakdown-graph

Attendee Seniority

mrna-Audience-seniority-graphic

Exhibition Floorplan

mRNA-US-Floorplan-1

Get in Touch

Take advantage of our bespoke sponsorship packages to achieve your commercial goals and bring better mRNA drugs to patients faster than ever before. Get in touch if you would like to get involved.

Alex Kacykowski

Senior Partnership Director
RNA Therapy Events

Nicholas Ramovic

Senior Partnerships Director
RNA Therapy Events

CAR-TCR23-227-1

Explore the Agenda

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tellus eros, eleifend eu dolor sed, vulputate sodales risus.

networking-glance

Sponsor the Event

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tellus eros, eleifend eu dolor sed, vulputate sodales risus.

mRNA-11 copy

Get Involved

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tellus eros, eleifend eu dolor sed, vulputate sodales risus.

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Utilizing Novel Technologies for mRNA Drug Manufacturing & Scale Up
Increasing Marketing Access & Commercialization Planning

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Optimizing Analytical Tools for mRNA Release & Nanoparticle Stability

Harmonizing Regulatory Documentation Guidance to De-Risk mRNA Drug Approval

Pioneering Delivery Solutions & Platform Innovations

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Optimizing Analytical Tools for mRNA Release & Nanoparticle Stability

Harmonizing Regulatory Documentation Guidance to De-Risk mRNA Drug Approval

Pioneering Delivery Solutions & Platform Innovations

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Optimizing Analytical Tools for mRNA Release & Nanoparticle Stability

Harmonizing Regulatory Documentation Guidance to De-Risk mRNA Drug Approval

Trailblazing mRNA-LNP Design, Screening & Synthesis Methods

Optimizing Analytical Tools for mRNA Release & Nanoparticle Stability

Harmonizing Regulatory Documentation Guidance to De-Risk mRNA Drug Approval